• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful Treatment of Paraneoplastic Cholestasis in Relapsed/Refractory Hodgkin Lymphoma With Bridging Therapy and Checkpoint Blockade.

作者信息

Peringeth Gopisree, Torka Pallawi, Wong Jerry, Hernandez-Ilizaliturri Francisco J

机构信息

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.

Department of Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.

出版信息

Clin Lymphoma Myeloma Leuk. 2020 Jun;20(6):e316-e319. doi: 10.1016/j.clml.2020.01.013. Epub 2020 Mar 13.

DOI:10.1016/j.clml.2020.01.013
PMID:32179034
Abstract
摘要

相似文献

1
Successful Treatment of Paraneoplastic Cholestasis in Relapsed/Refractory Hodgkin Lymphoma With Bridging Therapy and Checkpoint Blockade.采用桥接治疗和检查点阻断成功治疗复发/难治性霍奇金淋巴瘤伴副肿瘤性胆汁淤积症
Clin Lymphoma Myeloma Leuk. 2020 Jun;20(6):e316-e319. doi: 10.1016/j.clml.2020.01.013. Epub 2020 Mar 13.
2
Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting.低剂量 pembrolizumab 和 nivolumab 在复发和难治性经典霍奇金淋巴瘤中有效且安全：资源有限环境下的经验。
Hematol Oncol. 2020 Dec;38(5):726-736. doi: 10.1002/hon.2787. Epub 2020 Aug 20.
3
Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma.尼伏鲁单抗停药和复发或难治性霍奇金淋巴瘤患者的再治疗。
Ann Hematol. 2021 Mar;100(3):691-698. doi: 10.1007/s00277-021-04429-8. Epub 2021 Feb 2.
4
Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.在难治性霍奇金淋巴瘤中，联合使用放疗和纳武利尤单抗可产生完全的局部和远隔效应。
Radiat Res. 2018 Sep;190(3):322-329. doi: 10.1667/RR15048.1. Epub 2018 Jun 27.
5
Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD.异基因干细胞移植后伴有活动性移植物抗宿主病的复发难治性霍奇金淋巴瘤的低剂量程序性死亡受体1抑制治疗
Br J Haematol. 2019 Mar;184(5):840-844. doi: 10.1111/bjh.15186. Epub 2018 Mar 13.
6
Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy.尼妥珠单抗治疗伴肝衰竭和肝性脑病的 HIV 相关复发/难治性霍奇金淋巴瘤
J Immunother Cancer. 2017 Jun 20;5:49. doi: 10.1186/s40425-017-0252-3. eCollection 2017.
7
Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience.接受免疫检查点抑制剂治疗的经典型霍奇金淋巴瘤和非霍奇金淋巴瘤患者的临床、影像学表现、反应及预后：单中心经验
J Comput Assist Tomogr. 2020 Jul/Aug;44(4):619-626. doi: 10.1097/RCT.0000000000001043.
8
PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.PD-1 阻断可诱导异基因造血干细胞移植后复发的经典霍奇金淋巴瘤缓解。
J Immunother Cancer. 2017 Feb 21;5:11. doi: 10.1186/s40425-017-0211-z. eCollection 2017.
9
Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.识别和治疗多发性骨髓瘤和淋巴瘤中检查点抑制剂治疗的候选者。
Expert Rev Hematol. 2020 Apr;13(4):375-392. doi: 10.1080/17474086.2020.1733405. Epub 2020 Mar 2.
10
Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma.尼伏鲁单抗与 T 细胞 PD-1 结合的丧失预示霍奇金淋巴瘤的复发。
Int J Hematol. 2020 Mar;111(3):475-479. doi: 10.1007/s12185-019-02737-4. Epub 2019 Sep 19.

引用本文的文献

1
Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated With Brentuximab Vedotin: A Case Report and Review of the Literature.膈上经典型霍奇金淋巴瘤伴副肿瘤性肝内胆汁淤积经 Brentuximab Vedotin 成功治疗：病例报告及文献复习。
In Vivo. 2021 Jul-Aug;35(4):1951-1957. doi: 10.21873/invivo.12462.